Pohne

+ 7(495)414-68-15

Circle

Ru
En

Professional library

Advertising brochures

LDL Lipopak®, Lp(a) Lipopak®, Ig Adsopak® brochure

АВО Adsopak® brochure

Toxipak® brochure

Publications (reviews, clinical experience)

ABO Apheresis

Rimsevicius, 2016. Successful Adsorption of Anti-AB Antibodies with Multiple Personal Use Columns in AB0 Incompatible Kidney Recipients A Single Centre Experienc

Sushkov, 2013, P. Flexible immunosuppressive protocol for ABO-incompatible kidney transplantation

Double filtration plasmapheresis (DFPP)

Mednikov R. V., Rabinovich V.I., Kizlo S.N. et al. Double Filtration Plasmapheresis in Treatment of Patients With Co-Infection of Hepatitis C and Human Immunodeficiency Virus // Ther. Apher. Dial. – 2016. – Vol. 20, N 4. – P.413-419.

Fujiwara K., Kaneko S., Kakumu S. et al. Double filtration plasmapheresis and interferon combination therapy for chronic hepatitis C patients with genotype 1 and high viral load // Hepatol. Res. – 2007. – Vol. 37, N 9. – P.701-710.

LPS adsorption

Sokolov A.A., Gubanova S.N., Popov A.V., et al. LPS adsorption with Toxipak columns in treatment of sepsis // The 12th World Congress of International Society for Apheresis, KYOTO (poster presentation PP6-01) – 2019.

Selective Plasma Exchange

Bikhchandani J., Metcalfe M., Illouz S. et al. Extracorporeal liver perfusion system for artificial liver support across a membrane // J. Surg. Res. – 2011. – Vol. 171, N 1. – P.e139-e147.

Hanaoka A., Naganuma T., Takemoto Y. et al. Efficacy of selective plasma exchange as pre-Transplant apheresis in ABO-incompatible kidney transplantation // Ren. Replace. Ther. – 2019. – Vol. 5, N 1. – P.1-7.

Li M., Xue J., Liu J. et al. Efficacy of Cytokine Removal by Plasmadiafiltration Using a Selective Plasma Separator: In Vitro Sepsis Model // Ther. Apher. Dial. – 2011. – Vol. 15, N 1. – P.98-108.

Miyamoto S., Ohkubo A., Seshima H. et al. Removal Dynamics of Immunoglobulin and Fibrinogen by Conventional Plasma Exchange, Selective Plasma Exchange, and a Combination of the Two // Ther. Apher. Dial. – 2016. – Vol. 20, N 4. – P.342-347.

Miyamoto S., Ohkubo A., Seshima H. et al. Removal Dynamics of Autoantibodies, Immunoglobulins, and Coagulation Factors by Selective Plasma Exchange on Three Consecutive Days // Ther. Apher. Dial. – 2018. – Vol. 22, N 3. – P.255-260.

Mori T., Eguchi Y., Shimizu T. et al. A case of acute hepatic insufficiency treated with novel plasmapheresis plasma diafiltration for bridge use until liver transplantation // Ther. Apher. – 2002. – Vol. 6, N 6. – P.463-466.

Morris C., Rogerson D. The use of high-flux albumin haemofiltration (HFAF) with Evaclio EC-2CTM in the management of liver failure as a bridge to transplantation // J. Intensive Care Soc. – 2011. – Vol. 12, N 3. – P.228-233.

Nakae H., Igarashi T., Tajimi K. Selective Plasma Exchange With Dialysis in Patients With Acute Liver Failure // Ther. Apher. Dial. – 2012. – Vol. 16, N 5. – P.467-471.

Nakae H., Igarashi T., Tajimi K. et al. A case report of hepatorenal syndrome treated with plasma diafiltration (selective plasma filtration with dialysis) // Ther. Apher. Dial. – 2007. – Vol. 11, N 5. – P.391-395.

Lp(a) apheresis

Borberg H. Comparison of different Lp (a) elimination techniques: A retrospective evaluation // Transfus. Apher. Sci. – 2009. – Vol. 41, N 1. – P.61-65.

Jaeger B.R., Richter Y., Nagel D. et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events // Nat. Clin. Pract. Cardiovasc. Med. – 2009. – Vol. 6, N 3. – P.229-239.

Safarova M.S., Ezhov M. V., Afanasieva O.I. et al. Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography // Atheroscler. Suppl. – 2013. – Vol. 14, N 1. – P.93-99.

Ullrich H., Lackner K.J., Schmitz G. Lipoprotein(a) apheresis in severe coronary heart disease: An immunoadsorption method // Artif. Organs. – 1998. – Vol. 22, N 2. – P.135-139.

LDL apheresis

Bambauer R. Low-density lipoprotein apheresis: Clinical results with different methods // Artif. Organs. – 2002. – Vol. 26, N 2. – P.133-139.

Bambauer R., Schiel R., Latza R. Low-density lipoprotein apheresis: An overview // Ther. Apher. – 2003. – Vol. 7, N 4. – P.382-390.

Blaha M., Lanska M., Blaha V. et al. Pregnancy in homozygous familial hypercholesterolemia — Importance of LDL-apheresis // Atheroscler. Suppl. – 2015. – Vol. 18. – P.134-139.

Bláha M., Cermanová M., Bláha V. et al. Safety and tolerability of long lasting LDL-apheresis in familial hyperlipoproteinemia // Ther. Apher. Dial. – 2007. – Vol. 11, N 1. – P.9-15.

Borberg H. 26 Years of LDL — Apheresis: A review of experience // Transfus. Apher. Sci. – 2009. – Vol. 41, N 1. – P.49-59.

Griskevicius A., Audzijoniene J., Griskevicius L. et al. The lipoproteins selections aphereses with LDL Lipopak 400. // Transfus. Apher. Sci. – 2013. – Vol. 48, N 2. – P.183.

Ig apheresis

Bilgir, 2008. Immunoadsorption method using immunoglobulin Adsopak in adult cases with ITP resistant to splenectomy and other medical therapies

Blaha, 2010. Extracorporeal Immunoglobulin Elimination for the Treatment of Severe Myasthenia Gravis

Pokrovsky, 2013. Ig apheresis for the treatment of severe DCM patients

Ptak, 2004. Changes of plasma proteins after immunoadsorption usingIg-Adsopak columns in patients with myasthenia gravis

Useful links

ASFA Guidelines on the Use of Therapeutic Apheresis in Clinical Practice, 2019

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue

JSFA Guidelines on the Use of Therapeutic Apheresis in Clinical Practice

The Japanese Society for Apheresis clinical practice guideline for Therapeutic Apheresis 2021

Video

Webinar "Therapeutic apheresis in ABO-incompatible transplantations", 12.11.2020

1. Dr. Arzumanov. Experience of ABO-incompatible kidney transplantation from a living related donor.

2. Prof. Schmidt. Apheresis in AB0-Incompatible Renal Transplantation.

3. Dr. Adamova. Pocard Ltd. presentation

4. Discussion

News

The 13th ISFA World Congress and the 3rd E-ISFA Congress

01.03.2021

Dear Colleagues! We would like to invite you to participate in сommon Congress the 13th World Congress of the International Society of Apheresis (ISFA) и the 3rd Congress of the European Group – International Society for Apheresis (E-ISFA). Time: 17-20 March, 2021 This is an online participation form. Registration for participants is required in advance.

Webinar «Immunoadsorption for Renal Disease and Transplantation»

15.02.2021

Dear Colleagues! We would like to invite you to participate in the webinar: «Immunoadsorption for Renal Disease and Transplantation». Moderator: Hamad Almojalli, Senior Consultant, Hospital§Research Center of Riyadh, Riyadh, Saudi Arabia. Speaker: Bernhard Schmidt, Prof., MD, M.Sc. (Clin Epi.), Hannover Medical School, Hannover, Germany. Time: 24 February, 2021, 8:30-9:30 PM

Webinar Therapeutic apheresis in ABO-incompatible transplantations

11.11.2020

Dear Сolleagues! Pocard Ltd. invites you to join the Webinar Therapeutic apheresis in ABO-incompatible transplantations. The webinar will take part at 2:00-3:30 PM (UTC+3) on November 12. Program 1. Introduction to the problem (5 min) Bernhard Schmidt, Prof., MD, M.Sc. (Clin Epi.), Hannover Medical School, Hannover, Germany, 2. Experience of ABO-incompatible kidney transplantation from

Toxipak is now CE certified!

01.11.2020

Toxipak is now CE certified! Pocard Ltd. received the CE mark approval for the Toxipak® columns! Toxipak® adsorption column is designed for the procedures of LPS adsorption — selective hemoperfusion of endotoxin (lipopolysaccharide) of Gram-negative bacteria in treatment of sepsis and septic shock. The Toxipak® columns are released in plastic cases